CenterBook Partners LP Buys 3,537 Shares of Astrazeneca Plc $AZN

CenterBook Partners LP raised its stake in shares of Astrazeneca Plc (NYSE:AZN) by 11.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,800 shares of the company’s stock after purchasing an additional 3,537 shares during the period. CenterBook Partners LP’s holdings in Astrazeneca were worth $6,107,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Manchester Capital Management LLC boosted its holdings in shares of Astrazeneca by 2,851.1% during the 4th quarter. Manchester Capital Management LLC now owns 2,715 shares of the company’s stock valued at $476,000 after purchasing an additional 2,623 shares during the last quarter. Hilton Head Capital Partners LLC bought a new position in shares of Astrazeneca during the 4th quarter valued at about $175,000. Fiera Capital Corp boosted its holdings in shares of Astrazeneca by 28.9% during the 4th quarter. Fiera Capital Corp now owns 8,915 shares of the company’s stock valued at $1,565,000 after purchasing an additional 1,997 shares during the last quarter. Endeavor Private Wealth Inc. bought a new position in shares of Astrazeneca during the 4th quarter valued at about $498,000. Finally, Twin Tree Management LP boosted its holdings in shares of Astrazeneca by 174.9% during the 4th quarter. Twin Tree Management LP now owns 19,631 shares of the company’s stock valued at $3,445,000 after purchasing an additional 45,832 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Up 0.1%

Shares of NYSE:AZN opened at $186.06 on Monday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The company has a 50-day moving average price of $190.84 and a 200 day moving average price of $185.34. The company has a market cap of $288.57 billion, a price-to-earnings ratio of 27.94, a PEG ratio of 1.59 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. As a group, equities research analysts predict that Astrazeneca Plc will post 9.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, May 13th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.